Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
JMP Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5
Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $6
Needham Reiterates Buy on Taysha Gene Therapies, Maintains $6 Price Target
Taysha Gene Therapies Analyst Ratings
Wells Fargo Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7.5
Wells Fargo Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)
Truist Financial Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $5 to $7.5
Taysha Gene Therapies Is Maintained at Buy by Chardan Capital
Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Chardan Capital
Taysha Gene Therapies Analyst Ratings
Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $6
Taysha Gene Therapies Analyst Ratings
JMP Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5
JMP Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5
Buy Rating for Taysha Gene Therapies Due to Safer Administration Method and Lower Viral Dose
Taysha Gene Therapies Analyst Ratings
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $8
Taysha Gene Therapies Is Maintained at Buy by Chardan Capital